Clinical trials for professionals

The goal of this study is to find out the possible side effects of the study drug, whether the study drug can stop the growth or spread of cancer cells in your body, how your body processes the study drug, and how certain biomarkers or small substances in your body change in response to the study drug.

The goal of this study is to find out how well an investigational drug called NM21-1480 works to treat the cancer he has, how well it is tolerated by patients with solid tumors, and whether it has any side effects.

The main objective of the study is to investigate whether the study medication (vafidemstat) works in the treatment of the negative symptoms of the disease, described above, as well as in the treatment of the loss of cognitive function in patients with schizophrenia, and also whether this medication is safe. The study also aims to learn more about the causes of the disease and how our body processes the study medication. It is known that there is a genetic variability in the population (which is...

The objective of this study is to evaluate the efficacy of navitoclax and its safety when administered in combination with ruxolitinib compared to ruxolitinib and placebo on their disease in patients with myelofibrosis who have not previously been treated with a standard treatment such as a JAK-2 inhibitor or similar drug. The study has two treatment groups and you will be randomly assigned to one of the two treatment groups.

The objectives of the study are as follows: -Define the most appropriate dose of SAR441000. -Identify possible side effects and risks. -To characterize how your body acts against SAR441000, including how it eliminates it (called pharmacokinetics or PK). -Assess the antineoplastic activity of SAR441000. -Determine the presence of immune biomarkers (factors present in blood and tumors that can predict the activity of a drug).

The purpose of this study is to evaluate the effects, good or bad, of ranibizumab administered through an ocular implant (also known as a Port Delivery System with ranibizumab or PDS device) in patients with wet AMD. The ocular implant delivers ranibizumab continuously (without interruption) over an extended period of time to the back of the eye and can be recharged by the study physician. The intention is to keep the implant in the eye permanently, unless it needs to be removed for medical reas...

This Phase 1/2 study is being conducted to analyze the effects of AMG 510 in the treatment of advanced solid tumors with the p.G12C mutation in KRAS.

The objective of this study is to evaluate XmAb24306 at different doses to determine if it is safe and to learn how your body processes the drug.

The purpose of this open-label extension study is to help us learn how safe and effective a new drug called bimekizumab is in the long-term treatment of hidradenitis suppurativa.